The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Classic psychedelics produce altered states of consciousness that individuals often interpret as meaningful experiences. Across a number of human studies, when the participant-rated intensity of the overall drug effects are statistically controlled for, certain subjective effects predict therapeutic and other desirable outcomes. Underlying neurobiological mechanisms are likely necessary but not sufficient to confer full and enduring beneficial effects. We propose that the subjective effects of psychedelics are necessary for their enduring beneficial effects and that these subjective effects account for the majority of their benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because psychedelics are not only beneficial in populations suffering from psychopathologies, but also for those without, enhancing social and cognitive skills such as empathy and creativity, but also general well-being (18, 112).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [112]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These associations could reflect target engagement (ketamine-induced glutamate release), leading to dissociative effects, a subsequent elicitation of synaptogenesis and resultant antidepressant response 28,56,57 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, in this state, individuals may more readily engage with their cognitive beliefs and emotional states with enhanced detachment and decentration, potentially leading to therapeutic outcomes [42, 43].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Given the dose-response relationship between the glutamate surge, synaptogenesis and antidepressant response following ketamine administration 28,56,57 , it is possible that the relationship between derealization and increased SV2A density observed here is mediated by glutamate release.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [57]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Self-citationNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Self-citationCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Self-citationPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citation
Cited by
Items 501–541 of 541
Cullen, J. (2026) · Person-Centered & Experiential Psychotherapies · doi:10.1080/14779757.2026.2651879
Athéa, H. (2024) · theses.fr (ABES) · doi:10.70675/d1402550z7fe9z4237z90d2z4845d24c1bde · Cited by 1
Raihan, A. (2026) · Journal of Behavioral and Cognitive Therapy · doi:10.1016/j.jbct.2026.100571
Associations between psychedelic use and migraine history in Swedish twins
Simonsson, O., Sun, S., Wesseldijk, L. W., Ullén, F., Osika, W., & Mosing, M. A. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261449385
“…of psychedelics on headache frequency in adults with migraine or other headache disorders may not be related to the subjective experience during the acute effects (Schindler et al., 2025b), which contrasts with findings on the effects of psyche-delics on mental health (Yaden and Griffiths, 2020).”
Psychedelic Use and Psychological Healing Among Gender Exploring Clients: Clinicians’ Perspectives
Cassidy, E. K., Riccardi, J., Healy, B., Golakoti, S. S. M., & Farvid, P. (2026) · Women & Therapy · doi:10.1080/02703149.2026.2667141 · Cited by 1
“…et al., 2016; Davis et al., 2021) and natu-ralistically for self-exploration, meaning-making, and identity-related inquiry (Davis et al., 2020; Yaden & Griffiths, 2021), particularly among marginalized communities facing disproportionate mental health burdens (Ching et al., 2023; Williams et…”
Simon, G., Tadmor, N., Evans, J., Luke, D., & Luoma, J. B. (2026) · Research Square · doi:10.21203/rs.3.rs-9695196/v1 · Cited by 1
Phenomenology and psychopharmacology: a mutually enlightening relationship?
Lopes, M. (2026) · Phenomenology and the Cognitive Sciences · doi:10.1007/s11097-026-10165-z
Laursen, D. R. T., Salazar, J., Jűrgens, G., & Hróbjartsson, A. (2026) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2026.112345
Bertollo, A. G., Wippel, V. A., Mingoti, M. E. D., Prediger, R. D., & Ignácio, Z. M. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179036
Ahmadian-Moghadam, S., Roshan‐Milani, S., & Saboory, E. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04151-x
“In humans, psilocybin-assisted therapy has shown robust ef fi cacy in treatment-resistant depression [125], end-of-life anxiety [126], post-traumatic stress disorder (PTSD), and substance use disorders[127].”
Kervadec, E., Pauline, M., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Piolino, P., Benyamina, A., Roméo, B., & Hacquet, R. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111770
Modlin, N. L., Elek, Z., Maggio, C., Agrawal, M., Lepow, L., Rucker, J., Stubley, J., & Guss, J. R. (2026) · Psychodynamic Psychiatry · doi:10.1521/pdps.2026.54.2.338
THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY
Osipowska, J., Kwolek, M., Judzińska, A., Piech, B., Sobczyńska, K., Ignarska, J., Terbosh, M., `Mzabi, S. K., Trojanowska, E., & Dubaj, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5605
Nacker, D., Kalus, L., Seth, A. K., Stone, J. M., Chis-Ciure, R., Lawson, G., Simpson, J., Sander, J. W., Bremner, S., Jones, C. I., et al. (2026) · Journal of Affective Disorders · doi:10.64898/2026.06.17.26355864
Mystical Experiences as Catalysts in Ketamine-Assisted Psychotherapy: A Case Study
Couceiro, M. J. S. T., Rodrigues, V. A., & Torres, N. M. C. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2696253
Averill, L. A., & Neitzke‐Spruill, L. (2026) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20260006
Integrated 5-HT2A–TrkB and G protein signaling in serotonergic psychedelic responses
Taddei-Tardon, M., Medina-Rodríguez, L., Maltman, J. L., Hudson, S., Potukanuma, S., Jiménez, J. H., Martin-Guerrero, S. M., González‐Maeso, J., & López‐Giménez, J. F. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03746-6 · Cited by 4
“Third, the use of YM254890 and pertussis toxin supports the involvement of G q/11 and PTX-sensitive G i/o dependent signalling, but does not identify the precise receptor –”
Tanuseputro, P., Docherty, J., Sun, X., Chan, M., & Gearin, A. K. (2026) · CNS Drugs · doi:10.1007/s40263-026-01324-6
“This challenge reflects a deeper question regarding the importance of subjective experience to treatment outcomes across all psych-edelics, as scales measuring mystical and peak experiences have correlated with therapeutic outcomes [21].”
Ketamine-induced analgesia and dissociation show distinct behavioral and neural correlates
Goldway, N., Jalon, I., Agbaria, Y., Pasternak, Y., Sar-El, R., Mirelman, D., Sarna, N., Green, N., Hendler, T., & Sharon, H. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02496-x
Classic Psychedelics for Treating Chronic Pain: Mechanism and Clinical Translation
Chen, H., Ke, B., & Jiang, R. (2026) · Molecules · doi:10.3390/molecules31152611
“A current mechanistic and translational debate in the field centers on whether the intense, altered state of consciousness (the hallucinogenic experience) is a prerequisite for therapeutic efficacy or merely a byproduct of 5-HT2A receptor activation [176,177].”
Retreat from racism: A psychedelic group experience for racial stress and trauma
Rosal, S. P., Faber, S., MacIntyre, M. M., & Williams, M. (2026) · Psychedelics · doi:10.1016/j.psyche.2026.100031
Schmitz, C. N., Bernardic, M., Vlădoiu, A.-D., Harris, R., Carmana, D., Kärtner, L., Oberthür, G., Gründer, G., & Adolphi, H. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111873 · Cited by 2
Molecules, meaning, and physiology: disentangling the active ingredients of psychedelic therapeutics
Kuypers, K. P. C. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1892474
“…meaning-making, and autonomic recalibration, with autonomic state influencing experiential depth (Bonnelle et al., 2024) and experiential intensity interacting with neurobiological plasticity mechanisms to influence the durability of therapeutic effects (Yaden and Griffiths, 2020) (Figure 2).”
Die Phänomenologie der psychedelischen Erfahrung
Schmidt, C., & Jungaberle, H. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21293-2.00005-8
Ross, B. M. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00517
Jaeckel, L., Logvinski, D., Kanana, M., Müller, F., Rohner, N., Becker, A. M., Liechti, M. E., & Sterzer, P. (2026) · Neuroscience of Consciousness · doi:10.1093/nc/niag050
“…model of hallucinatory experience, and specific phenomenological features of this state seem to predict therapeutic effects of psychedelics in treating psychiatric conditions ( Vollenweider et al. 1998, Hermle and Kraehenmann 2016, Aday et al. 2020, Yaden and Griffiths 2021, Aqil and Roseman 2022).”
Mele, M. L., & Federici, S. (2026) · Springer eBooks · doi:10.1007/978-981-92-1629-1_201-1
Passie, T., & van Elk, M. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261478606
“We note that in contemporary psychedelic science, we witness a similar debate about the relevance of subjective experiences compared to the biochemical effects of psychedelics for therapeutic efficacy (Olson, 2020; Yaden and Griffiths, 2020) – a debate that as-of-yet appears to be unresolved.”
Why taking the trip out of psychedelic medicine is a mistake
Heller, J., & Hendlin, Y. H. (2026) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2026.105487
Pobihuszka, D. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00489
Lawrence, D. W., Doss, M. K., & O’Connor, A. R. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2026.2729618
Simon, G., Hopper, J. W., Cherniak, A. D., Cassidy, E. K., Skragge, M., & Granqvist, P. (2026) · Neuroethics · doi:10.1007/s12152-026-09672-2
Kjellgren, A., Lundberg, J., Yngwe, H., Ekman, C. J., Tiger, M., Ljunglöf, T., Stridh, F., & Beckman, M. (2026) · Research Square · doi:10.21203/rs.3.rs-10879308/v1
Mulvehill, S. (2026) · Current Sexual Health Reports · doi:10.1007/s11930-026-00428-w
Ethics of psychedelics in clinical research: a state-of-the-field review
Cheung, K., Jacobs, E., & Yaden, D. B. (2026) · JME Practical Bioethics · doi:10.1136/jmepb-2025-000035
Self-citationAbouEich, H. K., Izadi, A., Lifshitz, J., Olson, D. E., & Gurkoff, G. G. (2026) · Journal of Neurotrauma · doi:10.1177/08977151261495030
Evaluering av Videreutdanning i psykedelisk terapi
Brekke, E., Kielland, T., Falchenberg, I., & Lien, L. (2026) · Tidsskrift for Norsk psykologforening · doi:10.52734/efvg7086
BindingDB Entry 50020245: 2B Determined: The Future of the Serotonin Receptor 2B in Drug Discovery.
BindingDB (2024) · UC San Diego · doi:10.7270/q26h4nwp
Psychedelic tourism as a structured precision field: A predictive-processing framework
Zhang, W., & Zhang, F. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00538
Åkesson, M., Granqvist, P., Johansson, R., & Brulin, J. G. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1924069
“The intensity and character of the subjective experiences during the acute psychedelic state appear to be important for understanding subsequent therapeutic and psychological effects (39, 40).”
Metadata
- Authors
- Yaden, D. B., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Griffiths, Roland R.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-10
- Volume
- 4
- Issue
- 2
- Pages
- 568-572
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC8033615
- OpenAlex
- W3113263685
- Cited by
- 541
- References
- 28
- Citations by year
- 2026: 81 · 2025: 125 · 2024: 105 · 2023: 98 · 2022: 92 · 2021: 36 · 2020: 2
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Steven and Alexandra Cohen Foundation
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- psychedelics, subjective effects, treatment outcomes, altered states of consciousness, meaningful experiences, subjective experience, neurobiological mechanisms, psychedelic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.